Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
167 hedge funds and large institutions have $1.01B invested in Acorda Therapeutics in 2016 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 57 increasing their positions, 58 reducing their positions, and 27 closing their positions.
2% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 58
5% less funds holding
Funds holding: 175 → 167 (-8)
18% less capital invested
Capital invested by funds: $1.23B → $1.01B (-$227M)
26% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 27
33% less call options, than puts
Call options by funds: $14.5M | Put options by funds: $21.5M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$25.7M |
| 2 |
BC
Broadfin Capital
New York
|
+$15M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.5M |
| 5 |
Goldman Sachs
New York
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$21.6M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$13.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.32M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$8.37M |
| 5 |
Millennium Management
New York
|
-$7.9M |
ACOR Hedge Fund Activity: Q3 2016 in Review
167 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2016, worth a combined $1.01B — down 18% from $1.23B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ACOR and 20 opened new positions — a net loss of 7 holders — while 58 trimmed existing stakes and 57 added.
The largest buyer was Scopia Capital Management, adding an estimated $25.7M. The largest seller was Deerfield Management, cutting an estimated $21.6M.
- 167 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2016, down from 175 in Q2 2016.
- Funds reported $1.01B of Acorda Therapeutics stock for Q3 2016, down 18% quarter-over-quarter.
- 20 funds opened new Acorda Therapeutics positions in Q3 2016 and 27 closed out, a net change of -7 holders.
- The largest Acorda Therapeutics buyer in Q3 2016 was Scopia Capital Management, an estimated $25.7M added.
- The largest Acorda Therapeutics seller in Q3 2016 was Deerfield Management, an estimated $21.6M sold.
Based on aggregated 13F filings for Q3 2016.